This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Trelegy Ellipta
  • /
  • A Study to Evaluate Annual Rate of Exacerbations a...
Clinical trial

A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Read time: 2 mins
Last updated:25th Sep 2009
Identifier: NCT01017952

The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)


Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 1635 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: HZC102970: A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Study Start Date: September 25, 2009
Primary Completion Date: October 1, 2011
Study Completion Date: October 17, 2011

Arm:
- Experimental:
FF/GW642444 Inhalation Powder 100/25 mcg QD
- Experimental: FF/GW642444 Inhalation Powder 50mcg/25mcg QD
- Experimental: FF/GW642444 Inhalation Powder 200/25 mcg QD
- Experimental: GW642444 25mcg QD

Category Value
Date last updated at source 2017-07-07
Study type(s) Interventional
Expected enrolment 1635
Study start date 2009-09-25
Estimated primary completion date 2011-10-01

View full details